Open Peer Review on Qeios

Chimeric Fibril-reactive Monoclonal Antibody CAEL-101

National Cancer Institute

Source

National Cancer Institute. <u>Chimeric Fibril-reactive Monoclonal Antibody CAEL-101</u>. NCI Thesaurus. Code C117241.

A chimeric monoclonal antibody specifically targeting human immunoglobulin light chain (LC)-related fibrils, which may potentially be used in the treatment of light chainassociated (AL) amyloidosis. Upon administration, chimeric fibril-reactive monoclonal antibody CAEL-101 targets and binds to the amyloid-related, conformational epitope on LC-related fibrils. This inhibits fibrillogenesis, induces an Fc-mediated cellular inflammatory response, increases degradation and elimination of AL amyloidomas, and prevents systemic LC-associated amyloid deposits. In AL amyloidosis the amyloid fibrils are composed of immunoglobulin light chain fragments.